Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients with Bloodstream Infection Due to Gram-Negative Bacteria

Clinical Infectious Diseases

Volumn 65, Issue 10, 2017, Pages 1607-1614

  Vazquez Guillamet, M Cristina ^a   Vazquez, Rodrigo ^a   Micek, Scott T ^b   Kollef, Marin H ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimicrobial resistance; bacteremia; gram negative bacteria; Prediction

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM;

ACINETOBACTER; ADULT; ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CONTROLLED STUDY; DECISION TREE; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HOSPITAL; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NURSING HOME PATIENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS; RISK FACTOR; SEPTIC SHOCK; SERRATIA; STENOTROPHOMONAS; AGED; BACTEREMIA; BETA-LACTAM RESISTANCE; DRUG EFFECT; GRAM NEGATIVE INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY;

ADULT; AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMS; DECISION TREES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85032731379     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix612     Document Type: Article

References (35)

1. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
2. de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013; 19:860-8.
3. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013; 19:501-9.
4. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69.
5. Retamar P, Portillo MM, Lopez-Prieto MD, et al; SAEI/SAMPAC Bacteremia Group. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012; 56:472-8.
6. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45: 486-552.
7. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18:596.
8. Morata L, Cobos-Trigueros N, Martinez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56:4833-7.
9. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63:568-74.
10. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
11. Vazquez-Guillamet C, Scolari M, Zilberberg MD, Shorr AF, Micek ST, Kollef M. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med 2014; 42:2342-9.
12. M100 performance standards for antimicrobial susceptibility testing, 27th ed.. Available at: https://clsi. org/standards/products/microbiology/documents/m100/.. Accessed 6 March 2017.
13. Biggs D, Ville BD, Suen E. A method of choosing multiway partitions for classification and decision trees. J Appl Stat 1991; 18: 49-62.
14. Kass GV. An exploratory technique for investigating large quantities of categorical data. J R Stat Soc Ser C Appl Stat 1980; 29:119-27.
15. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61-111.
16. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781-8.
17. CDDEP maps dangerous trends in antibiotic resistance on a global scale for the first time. Available at: http://www. cddep. org/blog/posts/cddep-maps-dangerous- trends-antibiotic-resistance-global-scale-first-time. Accessed 6 March 2017.
18. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014; 78: 443-8.
19. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37: 1288-301.
20. Al-Hasan MN, Eckel-Passow JE, Baddour LM. Impact of healthcare-associated acquisition on community-onset gram-negative bloodstream infection: a population-based study: healthcare-associated gram-negative BSI. Eur J Clin Microbiol Infect Dis 2012; 31:1163-71.
21. Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected Clin Infect Dis 2009; 48:580-6.
22. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK; Centers for Disease Control and Prevention Epicenter Program. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011; 53:532-40.
23. Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56: 197-9.
24. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008; 198: 336-43.
25. Goodman KE, Lessler J, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum lactamase-producing organism. Clin Infect Dis 2016; 63:896-903.
26. Denis B, Lafaurie M, Donay JL, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis 2015; 39:1-6.
27. Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis 2014; 46:753-62.
28. Dan S, Shah A, Justo JA, et al. Prediction of fluoroquinolone resistance in gram-negative bacteria causing bloodstream infections. Antimicrob Agents Chemother 2016; 60:2265-72.
29. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015; 61:1071-80.
30. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338:232-8.
31. Micek ST, Heard KM, Gowan M, Kollef MH. Identifying critically ill patients at risk for inappropriate antibiotic therapy: a pilot study of a point-of-care decision support alert. Crit Care Med 2014; 42:1832-8.
32. Paul M, Andreassen S, Tacconelli E, et al; TREAT Study Group. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 2006; 58:1238-45.
33. Hilty M, Betsch BY, Bogli-Stuber K, et al. Transmission dynamics of extended-spectrum lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012; 55:967-75.
34. Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum-lactamase-producing Escherichia coli in community hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol 2016; 37:49-54.
35. Koliscak LP, Johnson JW, Beardsley JR, et al. Optimizing empiric antibiotic therapy in patients with severe-lactam allergy. Antimicrob Agents Chemother 2013; 57:5918-23.